WO2017179862A1 - 안정성이 개선된 her2에 특이적으로 결합하는 항체 - Google Patents
안정성이 개선된 her2에 특이적으로 결합하는 항체 Download PDFInfo
- Publication number
- WO2017179862A1 WO2017179862A1 PCT/KR2017/003827 KR2017003827W WO2017179862A1 WO 2017179862 A1 WO2017179862 A1 WO 2017179862A1 KR 2017003827 W KR2017003827 W KR 2017003827W WO 2017179862 A1 WO2017179862 A1 WO 2017179862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- binding fragment
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 58
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 57
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 45
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 28
- 229960000575 trastuzumab Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- -1 Leu Chemical group 0.000 description 6
- 238000005277 cation exchange chromatography Methods 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102220600742 Calmodulin-binding transcription activator 1_G53A_mutation Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102220475559 Radial spoke head 1 homolog_D56A_mutation Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102200154559 rs587776904 Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101001010823 Homo sapiens Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 102000057750 human ERBB3 Human genes 0.000 description 1
- 102000053810 human ERBB4 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 101150117196 tra-1 gene Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- the present invention relates to an improved stability of HER2 antibodies used for the prevention or treatment of HER2 (Human Epidermal Growth Factor Receptor 2) related diseases, particularly cancer.
- HER2 Human Epidermal Growth Factor Receptor 2
- the HER2 / neu (ErbB2) gene encodes 185 kDa transmembrane and glycoproteins and is one of a family of epidermal growth factor receptors (EGFRs).
- the HER2 protein consists of an extracellular domain of 620 amino acid residues, a transmembrane domain of 23 amino acid residues and an intracellular domain of 490 amino acid residues having tyrosine kinase activity (Akiyama T, et al., Science , 232 ( 4758): 1644-1646 (1986).
- trastuzumab antibodies commercialized as Herceptin TM , US Pat. No. 5,821,337): Sapino, A., et al., Annals of Oncology (2007) 18: 1963-1968; Bussolati, G, et al., British Journal of Cancer (2005) 92, 1261-1267; and Glazyrin A, et al., J Histology & Cytochemistry (2007) 55 (1): 25-33.
- trastuzumab antibodies have been commercially successful, these antibodies are only effective in some patients with HER2 overexpression. Therefore, through co-administration with trastuzumab, there is an attempt to improve the prognosis of cancer patients who do not respond or have a slight response to trastuzumab.
- WO 2008/031531 discloses a method of inhibiting cancer metastasis by co-administering trastuzumab and pertuzumab, which bind the same target HER2, and WO 2014/185704 discloses a different method of trastuzumab and HER2.
- a method of displaying anticancer activity by co-administering hz1E11 that binds to an epitope is disclosed.
- Improving the stability of therapeutic antibodies may be a way to increase the overall efficiency, such as reducing costs, increasing efficacy, and reducing side effects. Therefore, studies have been carried out to secure antibodies with improved stability through modifications to the sequences of therapeutic antibodies (WO 2010/047509; Diepold, K., et al., PLos One (2012) 7 (1): e30295; Correia, IR., MAbs (2010) 2 (3): 221-232).
- the present inventors have tried to improve the structural stability of the antibody hz1E11 (refer to Korean Patent No. 1346346) already developed by the present inventors.
- Structural stability of the antibody is an important consideration in the commercial development of the drug, if the stability of the structure is not good quality control is disadvantageous, the efficacy is reduced and the side effects are increased.
- the inventors have discovered four amino acid residues that can significantly affect stability among amino acid residues at various positions of hz1E11, and prepared substitution variants of these amino acid residues to improve stability and improve productivity and efficacy with the parent antibody. A similar variant of hz1E11 was completed.
- HER2 Human Epidermal Growth Factor Receptor 2
- Another object of the present invention is to provide a nucleic acid molecule encoding an antibody or antigen-binding fragment thereof against HER2 which exhibits improved stability.
- Still another object of the present invention is to provide a recombinant vector comprising the nucleic acid molecule.
- Another object of the present invention to provide a host cell transformed with the recombinant vector.
- Another object of the present invention to provide a pharmaceutical composition for preventing or treating cancer.
- Still another object of the present invention is to provide a method for preventing or treating cancer, comprising administering the pharmaceutical composition for preventing or treating cancer to a subject.
- Still another object of the present invention is to provide a kit for diagnosing cancer.
- the invention provides (a) (i) complementarity determining region (HDR) CDR1 of SEQ ID NO: 1, (ii) CDRH2 of SEQ ID NO: 2, and (iii) SEQ ID NO: 3 A heavy chain variable region comprising a CDRH3 of; At least one of a fourth amino acid residue and a fifth amino acid residue in the second sequence is mutated to another amino acid; (b) for Human Epidermal Growth Factor Receptor 2 (HER2) exhibiting improved stability comprising a light chain variable region comprising CDRL1 of SEQ ID NO: 4, CDRL2 of SEQ ID NO: 5 and CDRL3 of SEQ ID NO: 6 An antibody or antigen binding fragment thereof is provided.
- HDR complementarity determining region
- the present inventors have tried to improve the structural stability of the antibody hz1E11 (refer to Korean Patent No. 1346346) already developed by the present inventors.
- Structural stability of the antibody is an important consideration in the commercial development of the drug, if the stability of the structure is not good quality control is disadvantageous, the efficacy is reduced and the side effects are increased.
- the inventors have discovered four amino acid residues that can significantly affect stability among amino acid residues at various positions of hz1E11, and prepared substitution variants of these amino acid residues to improve stability and improve productivity and efficacy with the parent antibody. A similar variant of hz1E11 was completed.
- amino acid residues are located in CDRH2 of the heavy chain variable region.
- the fourth and fifth amino acid residues of CDRH2 of SEQ ID NO: 2 are residues that affect the structural stability. When at least one of the two amino acids is substituted with another amino acid, stability is improved while maintaining the productivity and efficacy of the parent antibody.
- Asn, the fourth amino acid residue of CDRH2, may be substituted with any other amino acid.
- the fourth amino acid residue in SEQ ID NO: 2 of the CDRH2 is substituted with Ala, Gly, Cys, Ile, Leu, Met, Phe, Trp or Val, and more specifically, Ala, Gly, Substituted with Ile, Leu or Val, even more specifically with Ala or Gly, most particularly with Ala.
- Gly the fifth amino acid residue of CDRH2, may be substituted with any other amino acid.
- the fifth amino acid residue in SEQ ID NO: 2 of the CDRH2 is substituted with Ala, Cys, Ile, Leu, Met, Phe, Trp or Val, and more specifically, Ala, Ile, Leu or Substituted with Val, even more specifically with Ala or Val, most particularly with Ala.
- the amino acid substitution strategy adopted in the present invention is to replace the original amino acid with another amino acid, wherein the replacing amino acid is selected to have a structurally small and stable R- group having the least reactivity possible.
- the CDRH2 of the substitution-mutated SEQ ID NO: 2 sequence includes the amino acid sequence of SEQ ID NO: 9, the amino acid sequence of SEQ ID NO: 10 or the amino acid sequence of SEQ ID NO: 11 .
- the variant antibody of the present invention may improve stability by adding mutations to the light chain variable region in addition to the heavy chain variable region.
- the variable region of the antibody of the present invention comprises the amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 14.
- the invention provides (a) (i) complementarity determining region (HDR) CDR1 of SEQ ID NO: 1, (ii) CDRH2 of SEQ ID NO: 2, and (iii) SEQ ID NO: 3 A heavy chain variable region comprising the CDRH3 of the amino acid sequence of; And (b) a light chain variable region comprising SEQ ID NO: 8, wherein at least one of the 56th amino acid residue and the 57th amino acid residue of the SEQ ID NO: 8 sequence is substituted and substituted with another amino acid,
- HER2 Human Epidermal Growth Factor Receptor 2
- two amino acid residues are located in the framework region, not in the CDRs of the light chain variable region.
- 56th amino acid residue and 57th amino acid residue of SEQ ID NO: 8 are residues that affect the structural stability.
- stability is improved while maintaining the productivity and efficacy of the parent antibody.
- Asp the 56th amino acid residue of SEQ ID NO: 8, can be substituted with any other amino acid.
- the 56th amino acid residue of SEQ ID NO: 8 is substituted with Ala, Gly, Cys, Ile, Leu, Met, Phe, Trp or Val, and more specifically, Ala, Gly, Ile, Substituted with Leu or Val, even more specifically with Ala or Gly, most specifically with Ala.
- the 57th amino acid residue of SEQ ID NO: 8 can be substituted with any other amino acid.
- the 57th amino acid residue of SEQ ID NO: 8 is substituted with Ala, Cys, Ile, Leu, Met, Phe, Trp or Val, and more specifically, with Ala, Ile, Leu or Val Substituted, and more specifically, substituted with Ala or Val, most specifically with Ala.
- the amino acid sequence of the substitution-mutated SEQ ID NO: 8 sequence includes the amino acid sequence of SEQ ID NO: 12, amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14 of the sequence do.
- Antibodies of the invention have excellent killing or proliferative ability against cancer cells of various HER2-expressing.
- the term “killing” or “proliferation suppression” used while referring to cancer cells is used interchangeably.
- antibody refers to a specific antibody to HER2, which includes antigen binding fragments of antibody molecules as well as complete antibody forms.
- a complete antibody is a structure having two full length light chains and two full length heavy chains, each of which is linked by heavy and disulfide bonds.
- the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), and gamma 3 ( ⁇ 3). ), Gamma 4 ( ⁇ 4), alpha 1 ( ⁇ 1) and alpha 2 ( ⁇ 2).
- the constant regions of the light chains have kappa ( ⁇ ) and lambda ( ⁇ ) types (Cellular and Molecular Immunology, Wonsiewicz, MJ, Ed., Chapter 45, pp. 41-50, WB Saunders Co. Philadelphia, PA (1991); Nisonoff, A., Introduction to Molecular Immunology, 2nd Ed., Chapter 4, pp. 45-65, sinauer Associates, Inc., Sunderland, MA (1984)).
- the term “antigen binding fragment” means a fragment having antigen binding function and includes Fab, F (ab '), F (ab') 2 , Fv, and the like.
- Fab in the antibody fragment has a structure having a variable region of the light and heavy chains, a constant region of the light chain and the first constant region of the heavy chain (C H1 ) having one antigen binding site.
- F (ab ') 2 antibodies are produced by disulfide bonds of cysteine residues in the hinge region of Fab'.
- Double-chain Fv is a non-covalent bond in which the heavy chain variable region and the light chain variable region are linked, and the single-chain Fv is generally shared by the variable region of the heavy chain and the short chain variable region through a peptide linker. It may be linked by bond or directly at the C-terminus to form a dimer-like structure such as a double chain Fv.
- Such antibody fragments can be obtained using proteolytic enzymes (for example, restriction digestion of the entire antibody with papain can yield Fab and cleavage with pepsin can yield F (ab ') 2 fragment), or It can be produced through genetic recombination technology.
- proteolytic enzymes for example, restriction digestion of the entire antibody with papain can yield Fab and cleavage with pepsin can yield F (ab ') 2 fragment
- It can be produced through genetic recombination technology.
- the antibody is preferably in the form of Fab or in the form of a complete antibody.
- the heavy chain constant region may be selected from any one isotype of gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) or epsilon ( ⁇ ).
- the constant regions are gamma 1 (IgG1), gamma 3 (IgG3) and gamma 4 (IgG4), most preferably the gamma 1 (IgG1) isotype.
- the light chain constant region may be kappa or lambda type, preferably kappa type.
- preferred antibodies of the present invention are in Fab or IgG1 form with kappa ( ⁇ ) light chain and gamma 1 ( ⁇ 1) heavy chain.
- the term “heavy chain” refers to an entirety comprising a variable region domain V H and three constant region domains C H1 , C H2 and C H3 comprising an amino acid sequence having sufficient variable region sequence to confer specificity to the antigen. It means both length heavy chains and fragments thereof.
- the term “light chain” herein also refers to both the full-length light chain and fragments thereof comprising the variable region domain V L and the constant region domain C L comprising an amino acid sequence having sufficient variable region sequence to confer specificity to the antigen. do.
- complementarity determining region refers to the amino acid sequences of the hypervariable regions of immunoglobulin heavy and light chains (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., US Department of Health and Human Services, National Institutes of Health (1987)).
- the heavy chains (CDRH1, CDRH2 and CDRH3) and light chains (CDRL1, CDRL2 and CDRL3) each contain three CDRs. CDRs provide key contact residues for the antibody to bind antigen or epitope.
- Antibodies of the invention include monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain Fvs (scFV), single chain antibodies, Fab fragments, F (ab ') fragments, disulfide-binding Fvs (sdFV) And anti-idiotype (anti-Id) antibodies, epitope-binding fragments of the antibodies, and the like.
- the present invention provides a nucleic acid molecule encoding the antibody to the HER2 of the present invention or an antigen-binding fragment thereof.
- nucleic acid molecule is meant to encompass DNA (gDNA and cDNA) and RNA molecules inclusively, and the nucleotides that are the basic structural units in nucleic acid molecules are naturally modified nucleotides, as well as modified sugar or base sites. Analogues (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews , 90: 543-584 (1990)).
- the present invention provides a recombinant vector comprising the nucleic acid molecule of the present invention described above.
- vector refers to a plasmid vector as a means for expressing a gene of interest in a host cell; Cosmid vector; And viral vectors such as bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors, and the like.
- the nucleic acid molecule encoding the light chain variable region and the nucleic acid molecule encoding the heavy chain variable region in the vector of the present invention are operatively linked with the promoter.
- operably linked refers to the functional binding between a nucleic acid expression control sequence (eg, an array of promoters, signal sequences, or transcriptional regulator binding sites) and other nucleic acid sequences, thereby The regulatory sequence will control the transcription and / or translation of said other nucleic acid sequence.
- a nucleic acid expression control sequence eg, an array of promoters, signal sequences, or transcriptional regulator binding sites
- the recombinant vector system of the present invention can be constructed through various methods known in the art, and specific methods thereof are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory Press (2001). This document is incorporated herein by reference.
- Vectors of the present invention can typically be constructed as vectors for cloning or vectors for expression.
- the vector of the present invention can be constructed using prokaryotic or eukaryotic cells as hosts.
- promoters derived from the genome of mammalian cells e.g., metallothionine promoter, ⁇ -actin promoter, human heroglobin promoter and Human muscle creatine promoter
- promoters derived from mammalian viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, tk promoter of HSV, mouse breast tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of Moroni virus, promoter of Epstein Barr virus (EBV) and promoter of Loews sacoma virus (RSV)
- adenovirus late promoter vaccinia virus 7.5K promoter
- SV40 promoter cytomegalovirus promoter
- tk promoter of HSV e.g., mouse breast tumor virus (MMTV) promoter
- LTR promoter of HIV e.g., promoter of Moroni virus, promoter of Ep
- Vectors of the invention may be fused with other sequences to facilitate purification of the antibody expressed therefrom.
- Sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
- the protein expressed by the vector of the present invention is an antibody
- the expressed antibody can be easily purified through a Protein A column or the like without additional sequences for purification.
- the expression vector of the present invention as an optional marker, and includes antibiotic resistance genes commonly used in the art, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neo There are genes resistant to mycin and tetracycline.
- the present invention provides a host cell transformed with the recombinant vector.
- Host cells capable of stably and continuously cloning and expressing the vectors of the present invention are known in the art and can be used with any host cell, for example, suitable eukaryotic host cells of the vector are monkey kidney cells (COS7: monkey). kidney cells, NSO cells, SP2 / 0, Chinese hamster ovary (CHO) cells, W138, baby hamster kidney (BHK) cells, MDCK, myeloma cell lines, HuT 78 cells and HEK-293 cells Including but not limited to.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (a) a pharmaceutically effective amount of the HER2 antibody or antigen-binding fragment thereof of the present invention; And (b) provides a pharmaceutical composition for preventing or treating cancer comprising a pharmaceutically acceptable carrier.
- the present invention is directed to an antibody or antigen-binding fragment thereof according to the above-described HER2 of the present invention; And it provides a pharmaceutical composition for preventing or treating cancer comprising a histidine-buffer containing 1 to 200 mM histidine.
- the concentration of histidine contained in the histidine-buffer may be 1 to 200 mM, more specifically 1 to 150 mM, 1 to 100 mM, 1 to 50 mM, 1 to 40 mM, 1-30 mM, 1-20 mM, and most specifically 10 mM.
- the histidine-buffer may have a pH of 5 to 7, more specifically 5 to 6.5, 5.5 to 6.5, and most specifically 6 may be.
- the histidine-buffer may include 50-300 mM sodium chloride, more specifically 10-200 mM, 50-200 mM, 100-200 mM, most specifically 150 mM.
- the HER2 antibody or antigen-binding fragment thereof of the present invention shows superior stability even under severe conditions when stored in the histidine-buffered solution as compared to the case where stored in PBS buffer. Therefore, the pharmaceutical composition for preventing or treating cancer containing the histidine-buffer of the present invention has an excellent effect on improving the stability of the pharmaceutical composition comprising the HER2 antibody of the present invention or an antigen-binding fragment thereof as an active ingredient.
- the pharmaceutical composition of the present invention uses the above-described HER2 antibody or antigen-binding fragment thereof as an active ingredient, the contents in common between the two are repeated in order to avoid excessive complexity of the present specification by repeated description. Omit.
- the HER2 antibody of the present invention when co-administered with trastuzumab, results in a significantly improved apoptosis of cancer cells (especially breast cancer cells, more specifically HER2-expressing breast cancer cells). It can kill and is very effective for the treatment of cancer (especially breast cancer, more specifically HER2-expressing breast cancer).
- the pharmaceutical composition further comprises trastuzumab antibody.
- Cancers that can be prevented or treated by the compositions of the present invention include various cancers known in the art, for example breast cancer, ovarian cancer, gastric cancer, lung cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer , Colon cancer, colon cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, head and neck cancer, skin cancer, thyroid cancer, parathyroid cancer or ureter cancer.
- cancers that can be prevented or treated by the compositions of the present invention are HER2-expressing cancers, and more specifically HER2-expressing breast cancers.
- Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen.
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mann
- compositions of the present invention can be administered parenterally, such as intravenous, subcutaneous, intramuscular, intraperitoneal, topical, intranasal, pulmonary and rectal.
- Suitable dosages of the pharmaceutical compositions of the invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to reaction, Usually a skilled practitioner can easily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
- the daily dose of the pharmaceutical composition of the present invention is 0.0001-100 mg / kg.
- pharmaceutically effective amount means an amount sufficient to prevent or treat cancer.
- compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media or in the form of extracts, powders, suppositories, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.
- the pharmaceutical composition of the present invention further comprises trastuzumab antibody.
- trastuzumab refers to the antibody disclosed in US Pat. No. 5,821,337.
- the present invention provides a method for preventing cancer comprising administering to a subject a pharmaceutical composition comprising the above-described antibody against HER2 of the present invention or an antigen-binding fragment thereof as an active ingredient. Or provide a method of treatment.
- administer refers to administering a therapeutically effective amount of a composition of the invention directly to a subject (an individual) in need thereof so that the same amount is formed in the subject's body. Say that.
- a “therapeutically effective amount” of a composition means a content of the composition that is sufficient to provide a therapeutic or prophylactic effect to a subject to which the composition is to be administered, and includes “prophylactically effective amount”.
- the term “subject” includes, without limitation, human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon or rhesus monkey. Specifically, the subject of the present invention is a human.
- the method of preventing or treating cancer of the present invention is a method comprising administering a pharmaceutical composition for preventing or treating cancer, which is an aspect of the present invention, and thus avoids excessive complexity of the present disclosure with respect to overlapping contents. To omit them.
- the above-described antibodies to HER2 or antigen-binding fragments thereof of the present invention can be used for diagnosis, such as diagnosing cancer.
- the present invention provides a kit for diagnosing cancer, comprising the above-described antibody against HER2 of the present invention or an antigen-binding fragment thereof.
- the diagnostic kit of the present invention comprises the above-described HER2 antibody of the present invention or antigen-binding fragment thereof, and diagnoses the same disease as the pharmaceutical composition of the present invention. In order to avoid excessive complexity, the description is omitted.
- kits described above contain antibodies, they can basically be made suitable for various immunoassays or immunostaining.
- the immunoassay or immunostaining may include radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry, immunofluorescence staining and Immunoaffinity tablets, including but not limited to.
- the immunoassay or method of immunostaining is described in Enzyme Immunoassay , ET Maggio, ed., CRC Press, Boca Raton, Florida, 1980; Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology , Vol. 1, Walker, JM ed., Humana Press, NJ, 1984; And Ed Harlow and David Lane, Using Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, 1999, which is incorporated herein by reference.
- antibodies labeled with radioisotopes may be used to detect HER2 protein.
- a specific embodiment of the present invention comprises the steps of (i) coating the sample to be analyzed on the surface of the solid substrate; (ii) reacting the sample with a HER2 antibody as a primary antibody; (iii) reacting the resultant of step (ii) with the secondary antibody to which the enzyme is bound; And (iv) measuring the activity of the enzyme.
- Suitable as the solid substrate are hydrocarbon polymers (eg polystyrene and polypropylene), glass, metals or gels, most particularly microtiter plates.
- hydrocarbon polymers eg polystyrene and polypropylene
- glass e.g polystyrene and polypropylene
- metals or gels most particularly microtiter plates.
- Enzymes bound to the secondary antibody include, but are not limited to, enzymes catalyzing color reaction, fluorescence, luminescence or infrared reaction, for example, alkaline phosphatase, ⁇ -galactosidase, hose Radish peroxidase, luciferase and cytochrome P 450 .
- alkaline phosphatase When alkaline phosphatase is used as the enzyme binding to the secondary antibody, bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol-AS) as a substrate Chloronaphthol, aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin (bis) if colorimetric substrates such as -B1-phosphate) and enhanced chemifluorescence (ECF) are used, and horse radish peroxidase is used -N-methylacridinium nitrate), resorupin benzyl ether, luminol, Amflex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine), p-phenylenediamine-HCl and pyrocatechol (HYR), TMB (tetramethyl
- certain embodiments of the invention comprise the steps of: (i) coating a HERR2 antibody on the surface of a solid substrate as a capturing antibody; (ii) reacting the capture antibody with the sample; (iii) reacting the product of step (ii) with a HER2 detecting antibody to which a label which generates a signal is bound; And (iv) measuring the signal resulting from the label.
- the detection antibody carries a label which generates a detectable signal.
- the label may include chemicals (eg biotin), enzymes (alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase and cytochrome P 450 ), radioactive substances (eg C 14 , I 125 , P 32 and S 35 ), fluorescent materials (eg, fluorescein), luminescent materials, chemiluminescent and fluorescence resonance energy transfer (FRET).
- chemicals eg biotin
- enzymes alkaline phosphatase, ⁇ -galactosidase, horse radish peroxidase and cytochrome P 450
- radioactive substances eg C 14 , I 125 , P 32 and S 35
- fluorescent materials eg, fluorescein
- luminescent materials eg, chemiluminescent and fluorescence resonance energy transfer (FRET).
- FRET fluorescence resonance energy transfer
- Measurement of the final enzyme activity or signal in the ELISA method and the capture-ELISA method can be carried out according to various methods known in the art. If biotin is used as a label, the signal can be easily detected with streptavidin and luciferin if luciferase is used.
- Samples that may be applied to the kits of the present invention include, but are not limited to, cells, tissues or tissue-derived extracts, lysates or purified products, blood, plasma, serum, lymph or ascites.
- Antibodies of the invention can be used for in vivo or in vitro imaging.
- the present invention provides a composition for imaging comprising the above-described antibody of the present invention and a label bound conjugate for generating a detectable signal bound to the antibody.
- Labels that generate the detectable signal include T1 contrast material (eg, Gd chelate compound), T2 contrast material (eg, superparamagnetic material (eg, magnetite, Fe 3 O 4 , ⁇ -Fe 2 O 3 , manganese ferrite, cobalt) Ferrites and nickel ferrites)), radioisotopes (e.g., 11 C, 15 O, 13 N, P 32 , S 35 , 44 Sc, 45 Ti, 118 I, 136 La, 198 Tl, 200 Tl, 205 Bi, and 206 Bi), fluorescent materials (fluorescein, phycoerythrin, rhodamine, lissamine, and Cy3 and Cy5), chemiluminescent groups, magnetic particles, mass labels or electron-dense particles It is not limited to this.
- T1 contrast material eg, Gd chelate compound
- T2 contrast material eg, superparamagnetic material (eg, magnetite, Fe 3 O 4 , ⁇ -F
- the present invention improves the stability of the antibody by substituting specific site amino acid residues of the parent antibody, thereby improving the drug compatibility.
- the mutant antibody of the present invention has almost the same productivity and efficacy, and greatly improves stability.
- the variant antibodies of the present invention exhibit excellent properties such as reduced production cost, reduced efficacy, and reduced side effects in the development of HER2-specific antibodies.
- HER2 is an ELISA result of analyzing whether the antibody having improved stability specifically binds to HER2 among ErbB family proteins (HER1, HER2, HER3, and HER4) to which HER2 belongs.
- hz15E3, trastuzumab, AMG-888 (Li C. et al., Discov Med. 2013 Sep; 16 (87): 79-92) were used as control antibodies.
- Anti-HER2 Ab represents trastuzumab
- Anti-EGFR Ab represents hz15E3
- Anti-HER3 Ab represents AMG-888.
- 2nd only represents a negative control group.
- hIgG negative control with human IgG
- TRA trastuzumab
- hIgG represents negative control with human IgG and TRA represents trastuzumab.
- variable and constant region portions of the heavy and light chains were amplified and cloned.
- Primers used for amplification are shown in Table 2, using the above-described primers and GoTaq DNA polymerase (Promega, Cat. No. M3005) at 95 °C 30 seconds, 57 °C 30 seconds, 72 °C 60 seconds PCR The reaction was repeated 30 times.
- PCR products of the amplified variable region and the constant region were purified by using a Qiaquick gel extraction kit (QIAGEN, Cat. No. 28706) after electrophoresis on 1% agarose gel.
- the PCR product of the variable region and the PCR region of the constant region are mixed in the same amount, and then an overlap extension PCR is performed using the forward primer of the variable region and the reverse primer of the constant region.
- the gene product was prepared and purified in the same manner as above.
- the overlap extension PCR was carried out by repeating the reaction of GoTaq DNA polymerase (Promega, Cat. No. M3005) for 30 seconds at 94 °C, 30 seconds at 57 °C, 120 seconds at 72 °C.
- the cloning vector of the mutated antibody of Example 1 was constructed according to the method disclosed in Korean Patent No. 1434652.
- FreeStyle TM 293F Invitrogen, Cat. No. R790-07 animal cells were transiently transfected with polyethylenimine (Polyscience Inc., Cat. No. 23966) to transfect the cloned vector and removed from the cell culture.
- Modified antibodies were purified using Protein-A Ceramic HyperD F resin (PALL, Cat No. 20078-028). Purified antibodies were quantified using UV analysis, and concentration and purity were confirmed by Coomassie blue staining after SDS-PAGE.
- hz1E11.10 and hz1E11.20 transformed with only the heavy chain alone showed better productivity than the parental antibody hz1E11.
- hz1E11.01 and hz1E11.02, which modified only the light chain chain alone were found to be worse in productivity. It is shown in Table 4 that the antibody which modified the light chain and the heavy chain at the same time shows the productivity slightly lower than the productivity of the parent antibody hz1E11.
- ELISA was used as a method for confirming whether the antibody to HER2 having improved stability binds to the target HER2.
- ECD extracellular domain
- the extracellular domain (ECD) region of the ERBB family protein was produced using animal cells and used as an antigen. Cloning of the DNA in the form of the hinge and Fc region (CH 2 -CH 3 ) of human IgG1 at the C-terminus of ECD to pCEP4 vector (Invitrogen, Cat. No. V044-50) using HindIII and BamHI restriction enzymes It was. Subsequently, the cloned vector was transiently transfected with FreeStyle TM 293F (Invitrogen, Cat. No.
- EGFR-ECF-Fc HER2-ECD-Fc
- HER3-ECD-Fc ChromPure human IgG (hIgG, Jackson Immunoresearch Lab. Inc., Cat.No. 009-000-003) at a concentration of 1 ⁇ g / mL Costar
- TBS-T 0.05% Triton X-100
- 300 ⁇ l of TBS-T / SM 2% skim milk
- the stability of the HER2 antibody was added and the antibody was bound for 1 hour at 37 °C.
- the anti-mouse IgG-HRP (Pierce, Cat. No. 31439) was diluted 1: 5,000 in TBS-T / SM as a secondary antibody, and the antibody was bound for 1 hour at 37 ° C.
- TMB PurModics, Cat.No. TMBC-1000-01
- 1 N sulfuric acid sulfuric acid, DukSan, Cat. No. 254
- Absorbance at 450 nm was measured using Victor X3 (PerkinElmer, Cat. No. 2030-0030) and confirmed that it did not specifically bind to HER2-ECD-Fc.
- Anti-EGFR Ab (hz15E3), anti-HER2 Ab (trastuzumab), and anti-HER3 Ab (AMG-888), which bind to EGFR, were used as controls to confirm that ELISA was normally performed. It was confirmed that the eight antibodies modified to improve stability specifically binds only to HER2 (FIG. 1).
- Cell viability assay was performed to confirm the cell proliferation inhibitory effect of the modified antibodies to improve the stability.
- NCI-N87 cells a representative gastric cancer cell line overexpressing HER2, alone or in combination with trastuzumab.
- the developed antibody and trastuzumab were used in a 1: 1 ratio (weight ratio).
- NCI-N87 ATCC, Cat No. CRL-5822, 10,000 cells / well
- Final concentrations of the treated antibodies were up to 20 ⁇ g / mL for each antibody and were serially diluted 1: 4 and run at 9 concentrations.
- the developed antibody and trastuzumab were in a 1: 1 ratio (for example, in FIG. 3, TRA 1 ⁇ g / mL and the developed antibody 1 when the dose was 1 ⁇ g / mL). ⁇ g / mL).
- NCI-N87 cells were further cultured for 4 days, and then CCK-8 was added to the final 10% and treated at 37 ° C. for 3 hours. Thereafter, the absorbance was measured at 450 nm using Victor X-3. Absorbance of cells not treated with antibody was set at 100% and relative survival was calculated (FIGS. 2 and 3).
- HER2 antibodies with enhanced stability showed proliferation inhibitory effect against NCI-N87 cell line in response to trastuzumab. Moreover, the developed antibody was superior in inhibiting cancer cell proliferation with respect to NCI-N87 cell line compared with trastuzumab alone in combination with trastuzumab as in the parent antibody hz1E11 (FIGS. 2 and 3).
- the present inventors performed an acceleration / stress test (accelerated test, stress test) on the parent antibodies hz1E11 and mutant antibodies hz1E11.10 and hz1E11.11 obtained from CHO cells.
- Each of the above antibodies is buffered in PBS buffer (137 mM Sodium chloride, 2.7 mM potassium chloride, 4.3 mM sodium phosphate, 1.4 mM potassium, pH 7.4), or histidine buffer (10 mM Histidine, 150 mM Sodium chloride, pH 6.0).
- PBS buffer 137 mM Sodium chloride, 2.7 mM potassium chloride, 4.3 mM sodium phosphate, 1.4 mM potassium, pH 7.4
- histidine buffer 10 mM Histidine, 150 mM Sodium chloride, pH 6.0.
- SEC Size exclusion chromatography
- CEX cation-exchange chromatography
- Samples prepared above were prepared using a constant temperature and humidity cabinet (CEO No. TH-DG-150) and a refrigerator (JEO TECH, Cat No. CLG-150S), respectively. 5%), 40 ⁇ 3 °C (humidity 75 ⁇ 5%) and stored in a temperature / humidity conditions, and the stability of each sample was analyzed at 0 and 4 weeks from the storage time.
- the analysis of the sample was performed using an Agilent 1260 infinity HPLC instrument, and the size-exclusion chromatography confirmed the ratio of monomers to confirm the stability according to the conditions.
- the cation-exchange chromatography Stability was confirmed by checking the ratio of the main peak.
- each antibody protein was analyzed for monomer ratio analysis using 100 mM sodium phosphate (pH 6.8) (Monobasic, Fluka, Cat No.17844; Dibasic, Fluka, Cat No71633) solution mobile phase conditions under TSK-gel G3000SWXL (7.8 X 300 mm)
- a protein peak was detected at UV280 nm while flowing for 20 minutes at a rate of 0.8 mL / min.
- the aggregates of protein elute before the main peak from the column, and the monomer purity was calculated by comparing the peak area of the aggregate with the area of the main peak.
- the protein was diluted to 1 mg / mL with 10 mM sodium phosphate (pH 7.0) (Monobasic, Fluka, Cat No.17844; Dibasic, Fluka, Cat No.71633) buffer to 20 ⁇ L was injected into a Bio Mab (NP10, PK, 4.6 x 250 mm) HPLC column (Agilent, Cat No.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
모항체(hz1E11) | 아미노산 서열 |
중쇄 사슬의 가변 부위 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVAYIS NGGGSTY YPDTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHLGGTASFDYWGQGTLVTVSS |
경쇄 사슬의 가변 부위 | DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLAWYQQKPGKAPKLLIYVATSLA DG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNAYAPWTFGQGTKVEIK |
프라이머명 | 서열 |
F_N52aA | GTAGCCTACATCTCCGCCGGGGGCGGAAGTAC |
R_N52aA | GTACTTCCGCCCCCGGCGGAGATGTAGGCTAC |
F_G53A | CTACATCTCCAACGCCGGCGGAAGTACGTA |
R_G53A | TACGTACTTCCGCCGGCGTTGGAGATGTAG |
F_D56A | GCAACGAGTCTCGCTGCCGGTGTGCCTTCCAGA |
R_D56A | TCTGGAAGGCACACCGGCAGCGAGACTCGTTGC |
F_G57A | CGAGTCTCGCTGACGCCGTGCCTTCCAGATTT |
R_G57A | AAATCTGGAAGGCACGGCGTCAGCGAGACTCG |
- | 항체 | 변이 위치 |
변이된 항체 | hz1E11.10 | 중쇄 N52aA |
hz1E11.20 | 중쇄 G53A | |
hz1E11.01 | 경쇄 D56A | |
hz1E11.02 | 경쇄 G57A | |
hz1E11.11 | 중쇄 N52aA/경쇄 D56A | |
hz1E11.12 | 중쇄 N52aA/경쇄 G57A | |
hz1E11.21 | 중쇄 G53A/경쇄 D56A | |
hz1E11.22 | 중쇄 G53A/경쇄 G57A | |
모항체 | hz1E11 | - |
항체 | 배양 볼륨(ml) | 생산양(㎍) | 수율(mg/L) |
hz1E11.10 | 30 | 1.414 | 47.1 |
hz1E11.20 | 30 | 1.264 | 42.1 |
hz1E11.01 | 30 | 0.784 | 26.1 |
hz1E11.02 | 30 | 0.750 | 25.0 |
hz1E11.11 | 30 | 0.857 | 28.6 |
hz1E11.12 | 30 | 0.783 | 26.1 |
hz1E11.21 | 30 | 0.640 | 21.3 |
hz1E11.22 | 30 | 0.845 | 28.2 |
hz1E11 | 30 | 0.992 | 33.1 |
항체 | 온도 | 0 주(monomer;%) | 4 주(monomer;%) | 12 주(monomer;%) |
hz1E11 (PBS) | 4℃ | 97.8 | 99.0 | 98.2 |
25℃ | 98.6 | 97.8 | ||
40℃ | 96.7 | 95.4 | ||
hz1E11.10 (PBS) | 4℃ | 99.0 | 99.4 | 98.7 |
25℃ | 98.4 | 98.5 | ||
40℃ | 97.7 | 96.7 | ||
hz1E11.11 (PBS) | 4℃ | 98.5 | 99.4 | 98.2 |
25℃ | 98.0 | 97.6 | ||
40℃ | 96.9 | 95.0 |
항체 | 온도 | 0 주(main peak;%) | 4 주(main peak;%) | 12 주(main peak;%) |
hz1E11 (PBS) | 4℃ | 62.8 | 60.3 | 62.9 |
25℃ | 45.3 | 29.9 | ||
40℃ | 4.8 | 0.0 | ||
hz1E11.10 (PBS) | 4℃ | 77.4 | 80.4 | 66.9 |
25℃ | 63.0 | 42.6 | ||
40℃ | 38.5 | 0.0 | ||
hz1E11.11 (PBS) | 4℃ | 88.1 | 75.7 | 74.0 |
25℃ | 58.5 | 48.3 | ||
40℃ | 27.0 | 0.0 |
항체 | 온도 | 0 주(monomer;%) | 4 주(monomer;%) | 12 주(monomer;%) |
hz1E11 (His) | 4℃ | 98.0 | 99.2 | 98.1 |
25℃ | 99.0 | 98.3 | ||
40℃ | 97.3 | 97.0 | ||
hz1E11.10 (His) | 4℃ | 99.3 | 99.7 | 99.0 |
25℃ | 98.4 | 99.3 | ||
40℃ | 98.2 | 98.2 | ||
hz1E11.11 (His) | 4℃ | 99.0 | 100.0 | 98.6 |
25℃ | 98.1 | 98.7 | ||
40℃ | 98.0 | 97.9 |
항체 | 온도 | 0 주(main peak;%) | 4 주(main peak;%) | 12 주(main peak;%) |
hz1E11 (His) | 4℃ | 61.5 | 61.5 | 56.0 |
25℃ | 61.3 | 56.2 | ||
40℃ | 52.8 | 29.3 | ||
hz1E11.10 (His) | 4℃ | 78.8 | 70.7 | 81.7 |
25℃ | 69.1 | 69.2 | ||
40℃ | 62.0 | 46.6 | ||
hz1E11.11 (His) | 4℃ | 72.2 | 76.9 | 76.4 |
25℃ | 69.1 | 69.0 | ||
40℃ | 65.1 | 49.1 |
Claims (27)
- (a) (i) 서열목록 제1서열의 CDR(complementarity determining region)H1, (ii) 서열목록 제2서열의 CDRH2 및 (iii) 서열목록 제3서열의 CDRH3을 포함하는 중쇄 가변영역; 상기 서열목록 제2서열에서 4번째 아미노산 잔기 및 5번째 아미노산 잔기 중 최소 하나는 다른 아미노산으로 치환 변이된 것이고;(b) 서열목록 제4서열의 CDRL1, 서열목록 제5서열의 CDRL2 및 서열목록 제6서열의 CDRL3을 포함하는 경쇄 가변영역을 포함하는 개선된 안정성을 나타내는 HER2(Human EpidermalGrowth Factor Receptor 2)에 대한 항체 또는 그의 항원 결합 단편.
- 제 1 항에 있어서, 상기 서열목록 제2서열에서 4번째 아미노산 잔기는 Ala, Gly, Cys, Ile, Leu, Met, Phe, Trp 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 2 항에 있어서, 상기 서열목록 제2서열에서 4번째 아미노산 잔기는 Ala, Gly, Ile, Leu 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 3 항에 있어서, 상기 서열목록 제2서열에서 4번째 아미노산 잔기는 Ala 또는 Gly으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1 항에 있어서, 상기 서열목록 제2서열에서 5번째 아미노산 잔기는 Ala, Cys, Ile, Leu, Met, Phe, Trp 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 5 항에 있어서, 상기 서열목록 제2서열에서 5번째 아미노산 잔기는 Ala, Ile, Leu 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 6 항에 있어서, 상기 서열목록 제2서열에서 5번째 아미노산 잔기는 Ala 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1 항에 있어서, 상기 치환 변이된 서열목록 제2서열의 CDRH2는 서열목록 제9서열의 아미노산 서열, 서열목록 제10서열의 아미노산 서열 또는 서열목록 제11서열의 아미노산 서열을 포함하는 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1 항에 있어서, 상기 경쇄 가변영역은 서열목록 제12서열, 서열목록 제13서열 또는 서열목록 제14서열의 아미노산 서열을 포함하는 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- (a) (i) 서열목록 제1서열의 CDR(complementarity determining region)H1, (ii) 서열목록 제2서열의 CDRH2 및 (iii) 서열목록 제3서열의 아미노산 서열의 CDRH3을 포함하는 중쇄 가변영역; 및(b) 서열목록 제8서열을 포함하는 경쇄 가변영역을 포함하며, 상기 서열목록 제8서열의 56번째 아미노산 잔기 및 57번째 아미노산 잔기 중 최소 하나가 다른 아미노산으로 치환 변이된 것을 특징으로 하는, 개선된 안정성을 나타내는 HER2(Human EpidermalGrowth Factor Receptor 2)에 대한 항체 또는 그의 항원 결합 단편.
- 제 10 항에 있어서, 상기 서열목록 제8서열의 56번째 아미노산 잔기는 Ala, Gly, Cys, Ile, Leu, Met, Phe, Trp 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 11 항에 있어서, 상기 서열목록 제8서열의 56번째 아미노산 잔기는 Ala, Gly, Ile, Leu 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 12 항에 있어서, 상기 서열목록 제8서열의 56번째 아미노산 잔기는 Ala 또는 Gly으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 10 항에 있어서, 상기 서열목록 제8서열의 57번째 아미노산 잔기는 Ala, Cys, Ile, Leu, Met, Phe, Trp 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 14 항에 있어서, 상기 서열목록 제8서열의 57번째 아미노산 잔기는 Ala, Ile, Leu 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 15 항에 있어서, 상기 서열목록 제8서열의 57번째 아미노산 잔기는 Ala 또는 Val으로 치환된 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 10 항에 있어서, 상기 경쇄 가변병역은 서열목록 제12서열의 아미노산 서열, 서열목록 제13서열의 아미노산 서열 또는 서열목록 제14서열의 아미노산 서열을 포함하는 것을 특징으로 하는 항체 또는 그의 항원 결합 단편.
- 제 1 항 내지 제 17 항 중 어느 한 항의 HER2에 대한 항체 또는 그의 항원 결합 단편을 코딩하는 핵산 분자.
- 제 18 항의 핵산 분자를 포함하는 재조합 벡터.
- 제 19 항의 재조합 벡터로 형질전환 된 숙주세포.
- (a) 제 1 항 내지 제 17 항 중 어느 한 항의 HER2에 대한 항체 또는 그의 항원 결합 단편의 약제학적 유효량; 및 (b) 약제학적으로 허용되는 담체를 포함하는 암 예방 또는 치료용 약제학적 조성물.
- 제 21 항에 있어서, 상기 약제학적 조성물은 트라스투주맙 항체를 추가적으로 포함하는 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 17 항 중 어느 한 항의 HER2에 대한 항체 또는 그의 항원 결합 단편을 포함하는 암 진단용 키트.
- 제 1 항 내지 제 17 항 중 어느 한 항의 HER2에 대한 항체 또는 그의 항원 결합 단편; 및 1 내지 200 mM의 히스티딘을 포함하는 히스티딘-완충액을 포함하는 암 예방 또는 치료용 약제학적 조성물.
- 제 24 항에 있어서, 상기 히스티딘-완충액의 pH는 5 내지 7인 것을 특징으로 하는 암 예방 또는 치료용 약제학적 조성물.
- 제 25 항에 있어서, 상기 히스티딘-완충액은 50-300 mM의 염화 나트륨을 포함하는 것을 특징으로 하는 암 예방 또는 치료용 약제학적 조성물.
- 제 1 항 내지 제 17 항 중 어느 한 항의 HER2에 대한 항체 또는 그의 항원 결합 단편을 유효성분으로 포함하는 약제학적 조성물을 대상체(subject)에 투여하는 단계를 포함하는 암의 예방 또는 치료방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/093,486 US11248059B2 (en) | 2016-04-12 | 2017-04-12 | Antibody having improved stability and specifically binding to HER2 |
CA3020825A CA3020825C (en) | 2016-04-12 | 2017-04-12 | Antibodies specifically binding to her2 |
CN201780023274.4A CN109071672B (zh) | 2016-04-12 | 2017-04-12 | 稳定性改善的特异性地结合在人表皮生长因子受体2的抗体 |
JP2018554349A JP6713059B2 (ja) | 2016-04-12 | 2017-04-12 | 安定性が改善されたher2に特異的に結合する抗体 |
EP17782617.9A EP3444279B1 (en) | 2016-04-12 | 2017-04-12 | Antibody having improved stability and specifically binding to her2 |
ES17782617T ES2955743T3 (es) | 2016-04-12 | 2017-04-12 | Anticuerpo con estabilidad mejorada y que se une específicamente a HER2 |
AU2017251298A AU2017251298B2 (en) | 2016-04-12 | 2017-04-12 | Antibody having improved stability and specifically binding to HER2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160044747 | 2016-04-12 | ||
KR10-2016-0044747 | 2016-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017179862A1 true WO2017179862A1 (ko) | 2017-10-19 |
Family
ID=60042607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/003827 WO2017179862A1 (ko) | 2016-04-12 | 2017-04-12 | 안정성이 개선된 her2에 특이적으로 결합하는 항체 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11248059B2 (ko) |
EP (1) | EP3444279B1 (ko) |
JP (1) | JP6713059B2 (ko) |
KR (1) | KR101796277B1 (ko) |
CN (1) | CN109071672B (ko) |
AU (1) | AU2017251298B2 (ko) |
CA (1) | CA3020825C (ko) |
ES (1) | ES2955743T3 (ko) |
WO (1) | WO2017179862A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230071864A (ko) | 2021-11-15 | 2023-05-24 | 앱클론(주) | Cd137에 특이적으로 결합하는 어피바디 및 이의 용도 |
CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030074634A (ko) * | 2000-11-30 | 2003-09-19 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
US20100047230A1 (en) * | 2005-02-21 | 2010-02-25 | Hellenic Pasteur Institute | Anti her2/neu antibody |
US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
KR101453462B1 (ko) * | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
WO2015074528A1 (zh) * | 2013-11-19 | 2015-05-28 | 烟台荣昌生物工程有限公司 | 抗her2抗体及其缀合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
EP1392360B1 (en) * | 2001-06-01 | 2011-11-30 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
CA2517074A1 (en) * | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
WO2010047509A2 (ko) | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 dr5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
CN104311662B (zh) * | 2013-03-08 | 2017-06-23 | 上海赛伦生物技术股份有限公司 | 一种稳定性高的人源抗vegf抗体及其应用 |
-
2017
- 2017-04-11 KR KR1020170046881A patent/KR101796277B1/ko active IP Right Grant
- 2017-04-12 US US16/093,486 patent/US11248059B2/en active Active
- 2017-04-12 WO PCT/KR2017/003827 patent/WO2017179862A1/ko active Application Filing
- 2017-04-12 CN CN201780023274.4A patent/CN109071672B/zh active Active
- 2017-04-12 AU AU2017251298A patent/AU2017251298B2/en active Active
- 2017-04-12 EP EP17782617.9A patent/EP3444279B1/en active Active
- 2017-04-12 JP JP2018554349A patent/JP6713059B2/ja active Active
- 2017-04-12 CA CA3020825A patent/CA3020825C/en active Active
- 2017-04-12 ES ES17782617T patent/ES2955743T3/es active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030074634A (ko) * | 2000-11-30 | 2003-09-19 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
US20100047230A1 (en) * | 2005-02-21 | 2010-02-25 | Hellenic Pasteur Institute | Anti her2/neu antibody |
US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
KR101453462B1 (ko) * | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
WO2015074528A1 (zh) * | 2013-11-19 | 2015-05-28 | 烟台荣昌生物工程有限公司 | 抗her2抗体及其缀合物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3444279A4 * |
Also Published As
Publication number | Publication date |
---|---|
US11248059B2 (en) | 2022-02-15 |
CA3020825A1 (en) | 2017-10-19 |
ES2955743T3 (es) | 2023-12-05 |
CN109071672A (zh) | 2018-12-21 |
KR101796277B1 (ko) | 2017-11-13 |
EP3444279C0 (en) | 2023-07-26 |
JP6713059B2 (ja) | 2020-06-24 |
AU2017251298A1 (en) | 2018-11-29 |
JP2019521644A (ja) | 2019-08-08 |
KR20170117330A (ko) | 2017-10-23 |
US20190153118A1 (en) | 2019-05-23 |
EP3444279A1 (en) | 2019-02-20 |
CN109071672B (zh) | 2021-11-19 |
CA3020825C (en) | 2022-01-25 |
EP3444279B1 (en) | 2023-07-26 |
EP3444279A4 (en) | 2019-04-24 |
AU2017251298B2 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
WO2020076105A1 (ko) | 신규 항-c-kit 항체 | |
KR101748707B1 (ko) | c-Met에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 | |
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
KR101541927B1 (ko) | 인간 사이토메갈로바이러스 중화 항체 및 이의 용도 | |
WO2013051878A2 (en) | Antibody specifically binding to epitope in sema domain of c-met | |
WO2021091359A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2017179862A1 (ko) | 안정성이 개선된 her2에 특이적으로 결합하는 항체 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
JP2023521362A (ja) | Cd73免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用 | |
WO2020116963A1 (ko) | 엔도텔린 수용체 a 활성 조절 항체 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2022154288A1 (ko) | 단백질 키나아제 a의 촉매 서브 유닛 알파에 특이적으로 결합하는 단일클론항체 및 이를 활용한 암 진단 용도 | |
WO2022025585A1 (ko) | 항-lilrb1 항체 및 그의 용도 | |
WO2020242200A1 (ko) | 엔도텔린 수용체 a 결합력이 향상된 항체 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
JP2022550121A (ja) | Lifに特異的な結合分子及びその使用 | |
WO2023101438A1 (ko) | Smo 인간 항체 | |
WO2023027534A1 (ko) | 신규 항 muc1항체 및 이의 용도 | |
WO2018182266A1 (ko) | 항-emap ii 항체 및 이의 용도 | |
WO2022098173A1 (ko) | 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도 | |
WO2019035630A2 (ko) | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 | |
WO2022092644A1 (ko) | Wars 중화항체 및 이의 용도 | |
WO2024014619A1 (ko) | 사스-코로나 바이러스 2 중화 항체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018554349 Country of ref document: JP Kind code of ref document: A Ref document number: 3020825 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017782617 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017782617 Country of ref document: EP Effective date: 20181112 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17782617 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017251298 Country of ref document: AU Date of ref document: 20170412 Kind code of ref document: A |